An interventional study of Heart monitoring tools (data revision) and Control (Standard treatment) in Chronic Heart Failure, Heart Transplant Recipient and Left Ventricular Assist Device, sponsored by Puerta de Hierro University Hospital. Active, not recruiting at 6 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Puerta de Hierro University Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Heart Failure with a site in Greece — 21 open to participants now, 27 under way, 14 of them phase 3. Heart Failure · Greece.
Among the 105 studies in Heart Failure with a site in Greece, this one is the 41st largest by enrollment of the 84 interventional ones that give a count, is one of 12 that started in 2024, is one of 27 with no phase, reaches primary completion later than 7 of the 26 other live ones, and was the 98th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →21 of the 105 studies in Heart Failure with a site in Greece are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Greece, United States, Argentina and 29 more countries
Ages 18+
Bayer · Sites in Greece, United States, Argentina and 20 more countries
Ages up to 18
Novo Nordisk A/S · Sites in Greece, United States, Argentina and 24 more countries
Ages 18+
University Hospital of Patras · Sites in Greece
Ages 18+
Bayer · Sites in Greece, United States, Argentina and 20 more countries
Ages 6 mo–17 yrs
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 18 · Phase 3 36 · Phase 4 4
First in 1983; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 390 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 367 across the 84 interventional studies, 358 across the 20 observational. Of the 65 that completed or were terminated, 32 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 105 have an industry lead sponsor. The 10 most frequent:
Puerta de Hierro University Hospital is the lead sponsor of 48 studies on the registry; 12 are open to participants now.
Puerta de Hierro University Hospital has 6 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
7 of the studies in Heart Failure with a site in Greece that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT03339115Cardiovalve Ltd.AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System | 2026-12-31 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 105 studies in Heart Failure with a site in Greece, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to create a digital platform for managing patients with chronic heart failure, those with long-term ventricular assistance, or heart transplant recipients. This platform aims to help doctors make clinical decisions and change treatments based on continuous monitoring and the collection of medical, clinical, physiological, behavioral, psychosocial, and real-world data from these patients.
The ultimate goal is to reduce mortality and hospitalization rates for this group of patients while improving their quality of life, safety, and well-being.
To do this, participants will be divided into two groups:
All participating patients will receive a set of devices and sensors to collect data such as vital signs, physical activity, sleep quality, psychological and nutritional status, and environmental data. All this information will be gathered through a mobile app designed for the study.
The follow-up will last for 18 months, during which there will be 4 in-person medical visits (spaced 4 months apart). Participation in the study won't affect patients' scheduled medical visits related to their illness or their usual treatment.
Specifically, the devices that will be given to the patients and their required use will be as follows:
A Smartphone: This will have the app with the platform designed for the study. The patient must interact with it daily to enter data.
A Blood Pressure Monitor: The patient will need to take their blood pressure every day and send it via Bluetooth to the mobile platform (the connection setup will be done by the study team before giving it to the patients).
An Oxygen Saturation Monitor: The patient will need to check their oxygen levels daily and send the data via Bluetooth to the mobile platform (the connection setup will be done by the study team before giving it to the patients).
A Scale: The patient will need to weigh themselves daily and transmit the data via Bluetooth to the mobile platform (the connection setup will be done by the study team before giving it to the patients).
A Smartwatch: The patient must send data on their physical activity and sleep daily via Bluetooth to the mobile platform (the connection setup will be done by the study team before giving it to the patients).
Home Humidity and Temperature Sensors and a Home Gateway Device (Raspberry Pi): The patient will need to connect this last device to their home internet network. The connection setup will be done by the study team before giving it to the patients.
There are other data and information that the patient must manually enter into the app, such as daily body temperature, symptoms they experience (like increased fatigue or shortness of breath), or data on the functioning of the long-term ventricular assistance (controller parameters or alarm presence). Additionally, the app will show the patient's current medication, which they need to confirm they have taken correctly.
The scheduled visits during the study will take place at the Baseline and every four months. These visits will include an in-person medical visit, an electrocardiogram, a blood test, and a 6-minute walk test. Also, at each visit, a series of questionnaires will be given to assess the patient's cognitive, nutritional, and psychological state, as well as their quality of life and that of their primary caregivers. Some visits will also include more specific cardiac tests, like an echocardiogram or a cardiopulmonary exercise test.
If during the study follow-up, the treating doctors unexpectedly discover any information that affects the patient's health or quality of life, the patient will be informed immediately, even if it is unrelated to the study's purpose.
All data recorded throughout the study will be stored anonymously by the study platform.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The RETENTION platform will offer to the clinician in the experimental arm all the data gathered by the devices (smart watch, scale, oximeter, blood pressure monitor, temperature, medication adherence, weather and pollution indexes). along with artificial intelligence recommendations.
Device: Heart monitoring tools (data revision)
Patients in the control group will be monitored but the data will not be available to the clinicians nor the artificial intelligence recommendations.
Other: Control (Standard treatment)
data collected by the devices will be reviewed by the treating physician in the intervention group
Patients in the control group will be monitored but the information will not be available for the clinicians nor the artificial intelligence recommendations
Percentage of days lost due to unplanned cardiovascular hospitalization or all-cause death
Percentage of follow-up days lost due to CEC-adjudicated unplanned cardiovascular hospitalization or death from any cause, from randomization through the common 12-month horizon, comparing the remote patient monitoring and interventions (RPMI) group with the remote patient monitoring and usual care (RPMUC) group. Computed as 100 x days lost / days under observation through 12 months; after death, all remaining days to the 12-month horizon are counted as lost.
Time frame: From randomization through the common 12-month analysis horizon
Rates of all-cause mortality
Time frame: From enrollment to the end of follow-up (18 months, full individual follow-up); also analysed with administrative censoring at 12 months
Rates of cardiovascular mortality
Time frame: From enrollment to the end of follow-up (18 months, full individual follow-up); also analysed with administrative censoring at 12 months
Differences in time to first unplanned HF hospitalization
Time frame: From the enrollment to the end of the follow up (18 months)]
Differences in time to first unplanned cardiovascular hospitalization
Time frame: From the enrollment to the end of the follow up (18 months)]
Rate of total unplanned HF hospitalizations
Time frame: From the enrollment to the end of the follow up (18 months)
Rate of total unplanned cardiovascular hospitalizations
Time frame: From the enrollment to the end of the follow up (18 months)
Differences in days lost due to HF hospitalizations
Time frame: From the enrollment to the end of the follow up (18 months)]
Differences in the number of Smart device alarm notifications
Time frame: From the enrollment to the end of the follow up (18 months)
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score
Change from baseline to the month 12 visit. KCCQ from 0-100
Time frame: Baseline and month 12
Change in the levels of NT-proBNP
Between Baseline and last visit
Time frame: Baseline and month 12
Change in the Depression Score Patient Health Questionnaire 9 (PHQ-9)
Between baseline and last visit
Time frame: Baseline and month 12
Change in the Heart Failure Caregiver Questionnaire (HF-CQ version 5.0)
Between baseline and last visit
Time frame: Baseline and month 12
Difference in the rate of rejection needing treatment in heart transplant patients
Time frame: From the enrollment to the end of the follow up (18 months)
Driveline infection needing antibiotic in left ventricular assist device (LVAD) patients
Time frame: From the enrollment to the end of the follow up (18 months)
Differences in the rate of unplanned visit for heart failure requiring intravenous diuretics
Time frame: From the enrollment to the end of the follow up (18 months)
Difference in the number of visits outside the protocol
Time frame: From the enrollment to the end of the follow up (18 months)
Time to first unplanned cardiovascular hospitalization or all-cause death
Time from randomization to the first occurrence of unplanned cardiovascular hospitalization or death from any cause, whichever occurs first, comparing RPMI vs RPMUC.
Time frame: Up to 18 months (full individual follow-up); also analysed with administrative censoring at 12 months
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Started Apr 2024 (actual). Primary completion is estimated for Oct 2026, 30 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 30 months is close to that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Aug 2026 → Oct 2026 and completion Aug 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Puerta de Hierro University Hospital